

Julie Le Naour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4190917/publications.pdf>

Version: 2024-02-01

15
papers

698
citations

933264

10
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	Trial watch: STING agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777624.	2.1	148
2	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1771143.	2.1	116
3	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777625.	2.1	91
4	Gut Microbiota-Stimulated Innate Lymphoid Cells Support \hat{I}^2 -Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. <i>Cell Metabolism</i> , 2018, 28, 557-572.e6.	7.2	84
5	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>Oncolmmunology</i> , 2020, 9, 1796002.	2.1	63
6	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , 2019, 8, e1657375.	2.1	56
7	Trial watch: intratumoral immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1984677.	2.1	31
8	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
9	The ambiguous role of FPR1 in immunity and inflammation. <i>Oncolmmunology</i> , 2020, 9, 1760061.	2.1	26
10	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	20
11	FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin. <i>Oncolmmunology</i> , 2020, 9, 1755214.	2.1	15
12	Improved Swiss-rolling method for histological analyses of colon tissue. <i>MethodsX</i> , 2022, 9, 101630.	0.7	7
13	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. <i>Oncolmmunology</i> , 2021, 10, 1859064.	2.1	6
14	No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020, 9, 1857112.	2.1	4
15	A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients. <i>Oncolmmunology</i> , 2022, 11, 2059878.	2.1	3